E+H has advised Austrian clinical-stage biotechnology company Affiris on its exclusive license agreement with Frontier Biotechnologies to develop and commercialize the Affitope AT04 hypercholesterolemia treatment on the Chinese market. Sonn Patentanwalte and Advant Beiten reportedly also advised Affiris.
The transaction remains contingent on regulatory approval. Affiris will retain the rights to AT04 outside China.
According to E+H, Frontier Biotechnologies is a publicly-traded Chinese commercial-stage biopharmaceutical company.
"Affiris' proprietary compound Affitope AT04 is a potential candidate for first-in-class active immunotherapy targeting PCSK9. The efficacy of this therapy was recently confirmed in a large phase 1 clinical trial," the firm informed. "Hypercholesterolemia is a chronic disease associated with an increased risk of cardiovascular disease, the leading cause of death worldwide. The collaboration with Frontier Biotechnologies now enables AT04 to be further developed as a cost-effective and patient-friendly treatment alternative in China."
"This collaboration further validates our Affitome technology platform," Affiris CEO Noel Barrett commented. "It fuels our ongoing efforts to license AT04 globally as we see a growing need for efficacious treatments in hypercholesterolemia."
The E+H team was led by Partner Marco Steiner and Attorney Johannes Feilmair and included Partners Jana Eichmeyer and Judith Feldner and Associates Fabian Larcher and Alexander Reiter.
